Indication: For lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension
Pharmacology: Levobunolol is an ophthalmic beta-blocker, equally effective at β(1)- and β(2)-receptor sites. The levorotatory isomer of bunolol, levobunolol is used for the treatment of IOP due to open-angle glaucoma or ocular hypertension.
Mechanism Of Action: Levobunolol's mechanism of action in reducing IOP is believed to be due to a reduction of the production of aqueous humor via inhibition of adrenergically driven processes within the ciliary processes.
Drug Category: Sympatholytics; EENT Drugs; ATC:S01ED03
Interactions:
DrugBank: Interactions for Levobunolol
Interactions for Levobunolol:
Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy
with BETAGAN and epinephrine may occur.
Close observation of the patient is recommended when a beta-blocker is administered to patients receiving
catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of
hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.
Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists
should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.
In patients with impaired cardiac function, simultaneous use should be avoided altogether.
The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive
effects on prolonging atrioventricular conduction time.
Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to
the inhibition of each otherís metabolism.
Chemical IUPAC Name: 5-(2-hydroxy-3-tert-butylamino-propoxy)tetralin-1-one
